INO has been in the news 375% more than usual
Feb 25, 2026, 5:31 PM
-17.51%
What does INO do
Inovio Pharmaceuticals, based in San Diego, develops DNA medicines targeting infectious diseases, cancer, and HPV-related conditions, with key candidates including INO-3107 for recurrent respiratory papillomatosis. The company employs 122 people and utilizes CELLECTRA devices for DNA delivery.
INO has been in the news recently: The Gross Law Firm is advising Inovio Pharmaceuticals shareholders who purchased shares between October 10, 2023, and December 26, 2025, to register by April 7, 2026, due to a class action lawsuit filed for securities violations. Additionally, the Law Offices of Frank R. Cruz are inviting investors who suffered losses in Inovio Pharmaceuticals to join the securities fraud lawsuit by the same deadline.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.